Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 10/20 | 0.35 |
| ▸ | CTSK | P43235 | 6/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870402 | 0.83 | CTSS (0.42) | CTSSCTSKCTSL | |
| SCHEMBL6475446 | 0.80 | CTSS (0.48) | CTSSCTSKCTSLSMN1; SMN2 | |
| SCHEMBL6592618 | 0.76 | CTSS (0.43) | CTSSCTSKCTSL | |
| SCHEMBL6477138 | 0.74 | CTSS (0.44) | CTSSCTSKCTSLSMN1; SMN2 | |
| SCHEMBL6476174 | 0.74 | CTSS (0.41) | CTSSCTSKCTSLSMN1; SMN2 | |
| SCHEMBL7207843 | 0.73 | SMN1; SMN2 (0.39) | CTSKUSP2SMN1; SMN2TSHRRECQL | |
| SCHEMBL6957544 | 0.73 | ALDH1A1 (0.40) | CTSSSMN1; SMN2TSHRRECQLALDH1A1 | |
| SCHEMBL4449255 | 0.73 | CTSK (0.46) | CTSSCTSKCTSLUSP2SMN1; SMN2 | |
| SCHEMBL6651574 | 0.72 | SMN1; SMN2 (0.49) | CTSSCTSKUSP2SMN1; SMN2TSHR | |
| SCHEMBL6476113 | 0.71 | CTSS (0.47) | CTSSCTSKCTSLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132449-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| EP-1358174-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057248-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | CTSS 24/4885CTSK 58/4885CTSL 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.